Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
I don't think you are being at all cynical...
If PH are here to get institutions to buy in - they'll start with the post-consolidation price they think they can sell this at (with room for downward movement for safety) and everything else will be orchestrated to get to this point. If it is ÂŁ1.50 then the SP will be just above 3p going into the EGM. If it is ÂŁ3.00 then it will be 6p+ going into the EGM...
Now if only we knew what that figure was... ;-)
Thanks Mafuta and Bluedreamer
Despite investing for quite a few years... this is the first consolidation I've been involved/interested in. Aside from my interest in SAR, I'm genuinely interested in the process
Is this just in preparation? Or do the BoD already know they have enough votes?
Quality use of capital letters short-nuts :-)
Green bin
Thanks Lazarus - you too :-)
"Why not try to guess where the sp will be post news"
Hi Lazarus2 - Because, other than something coming from Sierra, the only news expected till the summer is the Tox report.
If I buy back in now - I'd like to be very close to the bottom. Otherwise I'm content to wait for good news. And yes, that will likely mean I'll miss out on the biggest gains - but my risk appetite for SAR has blunted considerably recently. Still see big potential here but I'm a lot more cautious than I was a year ago.
Thanks Slawin - I'm just trying to guesstimate where the bottom (pre news) might be
They are generating cash - just look back through the last few months contract win RNS.
I completely agree with your main point though. That cash balance is to reassure large pharmas who are booking studies 12 months ahead. A certain amount has to stay on the books.
The last (seemingly organised) SP drop seemed very reluctant to drop below 3p...
While I think the board have several serious issues to address... Today is just AIM (and any pharma related stock in particular) taking a massive kicking).
Just take a look at aim generally : https://www.lse.co.uk/share-prices/indices/ftse-aim-all-share/fallers.html
Especially anything in the pharma space. A day to switch off and do something else...
Hi ColSoul
I'm not having a go... but I disagree about Poolbeg. Their business model is developing pre-clinical and early stage clinical assets. This is a minimum of 12 to 18 months and probably longer. I'm not sure what you expected after 7 months?
Costs are relevant when the company has only just secured (HNWIs) enough money to keep going for a few years
"It baffles me why the anti-consolidators don't allow a bit more time before casting their no vote. What's the rush? I maintain that most are driven by a misguided need to give the BOD a telling off rather than a reasoned decision. Apologies to those whose knees are jerk free!"
An alternative view, cobalt, is why haven't the board outlined a detailed plan, including expected benefits, that would convince the reluctant?
Just saying they want to attract institutional investors (which inevitable means placing and dilution) isn't a great sales pitch.
Will look to add more should there be a big sell off come release day. ;)
I'll will also be freeing up some cash... for exactly this reason
Thanks wallyj - as always :-)
Just my opinion, but this is how I see it.
The consolidation is the first step to an institutional placing. SAR want this money to conduct Phase 1 (maybe 2?) trials themselves. This will mean dilution, how much depends on how far they want to take this on their own. This will also take a fair chunk of time as, honestly, SAR are not known for speed.
A yes vote means shareholders are ok with this approach.
A no vote means shareholders are not happy with this approach and would like SAR to rethink, and perhaps look at partnership options...
Elcap (who I respect very much as a poster from another board) said on another thread that this vote should be about consolidation only, not the BoD, the share price or perceived inadequacies with public relations. I agree with this - but would take it a step further. This vote is about the future direction of SAR. Do they continue to go it alone (and I'm sorry but the age profile of some senior people does come into consideration here) or do they look for strong partners to advance their work.
My inclination is probably obvious from the way my post is worded and everyone will need to make their own minds up.
I'll finish with this... It is shareholders that own the company, not the BoD. Meetings and votes are the only time you get to influence the direction of your investment. Are you voting yes because you believe in this direction... or because you want to believe in this direction?
When one post wonders like lobbin appear, with posts straight out of the derampers, handbook, it usually means good news is coming soon. Lobbin, don’t bother replying to me, you’re already filtered
I would hope that SAR have some positive news to drop soon. This is a lot to ask of PIs without something positive to throw our way